PLANNED VARICELLA VACCINE PROPHYLAXIS: TACTICS AND PROSPECTS


Cite item

Full Text

Abstract

The efficiency of planned chickenpox vaccine prophylaxis in infants has been proved using the data available in foreign publications. The highest epidemiological and immunological effects were observed after double vaccination within the immunization schedule. The epidemiological regularities of varicella in Russia and the results of a study of the immune structure of the population to the pathogen of this infection suggest that infants need primary vaccination in the second year of life before going to children’s preschool facilities. By taking into account the experience with combination vaccines against measles, rubella, and mumps and the prospect of using tetravaccine against these infections and varicella and to ensure a high coverage, the infants should be vaccinated against varicella in the same periods - at 12 months and 6 years.

Full Text

Restricted Access

About the authors

I. V MIKHEYEVA

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare, Moscow

Email: Irina_Mikheeva@mail.ru

E. V VORONIN

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare, Moscow

M. V ERMOLENKO

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare, Moscow

T. S SALTYKOVA

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare, Moscow

References

  1. Ясинский А.А. Ветряная оспа в Российской Федерации. Вакцинация 2009; 1.
  2. Воронин Е.М., Михеева И.В. К вопросу об оценке экономического ущерба от заболеваний, вызываемых вирусом ветряной оспы / Профилактическая медицина - практическому здравоохранению: Сб. научных статей МПФ ППО ММА им. И.М.Сеченова. Вып.3. - М.: ФЦГЭ Роспотребнадзора; 2007: 259-264.
  3. Шаханина И.Л., Горелов А.В., Лыткина И.Л., Толкушин А.Г. Экономическая оценка вакцинопрофилактики ветряной оспы на примере Москвы. Эпидемиол. и инфекц. бол. 2009; 3: 49-57.
  4. CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases. 2007.
  5. Guris D., Jumaan A.O., Mascola L. еt al. Changing varicella epidemiology in active surveillance sites - United States, 1995-2005. J. Infect. Dis. 2008; 197(suppl. 2): S71-S75.
  6. Reynolds M.A., Watson B.M., Plott-Adams K.K. et al. Epidemiology of varicella hospitalizations in the United States, 1995-2005. J. Infect. Dis. 2008; 197(suppl. 2): S120 -S126.
  7. Nguyen H.Q., Jumaan A.O., Seward J.F. Decline in mortality due tovaricella after implementation of varicella vaccination in the United States. New Engl. J. Med. 2005; 352: 450-458.
  8. Seward J., Marin M., Vazquez M. Varicella vaccine effectiveness in the US vaccination program: a review. J. Infect. Dis. 2008; 197: S82-S87.
  9. Marin M., Guris D., Chaves S.S. et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007; 56: 1-40.
  10. Chaves S.S., Gargiullo P., Zhang J.X. et al. Loss of vaccine-induced immunity to varicella over time. New Engl. J. Med. 2007; 356: 1121-1129.
  11. Varicella vaccines. WHO position paper. MMWR 1998; 73: 241-248.
  12. Kwong J.C., Tanuseputro P., Zagorski B. et al. Impact of varicella vaccination on health care outcomes in Ontario, Canada: Effect of a publicly funded program? Vaccine 2008; 26: 6006-6012.
  13. Passwell J.H., Hemo B., Levi Y. et al. Use of a computerized database to study the effectiveness of an attenuated varicella vaccine. Pediat. Infect. Dis. J. 2004; 23: 221-226.
  14. Kamiya H., Ihata T., Nii T. and Study Group on varicella Vaccination. Prospective nationwide surveillance on varicella vaccination. Report of Study Group on Adverse Reactions of Vaccination. Tokyo: Ministry of Health and Welfare; 1999: 161-164.
  15. Ozaki T., Nishimura N., Kajita Y. Experience with live varicella vaccine (Oka strain) in healthy Japanese subjects: 10 year survey at pediatric clinic. Vaccine 2000; 13: 2375-2380.
  16. Asano Y. Varicella vaccine: the Japanese experience. J. Infect. Dis. 1996; 174 (suppl. 3): S310-S313.
  17. Asano Y., Yazaki T., Ito S. et al. Contact infection from live varicella vaccine recipients. Lancet 1976; 1: 965.
  18. Asano Y., Itakura N., Hiroishi Y. et al. Viral replication and immunologic responses in children naturally infected with varicella zoster virus and in varicella vaccine recipients. J. Infect. Dis. 1985; 152: 863-868.
  19. Sosa L.E., Hadler J.L. Epidemiology of varicella in Connecticut 2001-2005. J. Infect. Dis. 2008; 197(suppl. 2): S90-S93.
  20. Quian J., Ruttimann R., Romero C. et al. Impact of universal varicella vaccination of one year-olds in Uruguay: 1997-2005. Arch. Dis. Child. 2008; 93: 845-850.
  21. Jumaan A.O., Yu O., Jackson L.A. et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J. Infect. Dis. 2005; 191: 2002-2007.
  22. Zhou F., Harpaz R., Jumaan A.O. et al. Impact of varicella vaccination on health care utilization. J.A.M.A. 2005; 294: 797-802.
  23. Shapiro E.D., Vazquez M., Esposito D. et al. Effectiveness of 2 doses of varicella vaccine in children. J. Infect. Dis. 2011; 203: 312-315.
  24. Michalik D.E., Steinberg S.P. , LaRussa P.S. et al. Primary vaccine failure after 1 dose of varicellavaccine in healthy children. J. Infect. Dis. 2008; 197: 944 -949.
  25. Arvin A.M., Gershon A.A. Live attenuated varicella vaccine. Ann. Rev. Microbiol. 1996; 50: 59-100.
  26. Bergen R.E., Diaz P.S., Arvin A.M. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. J. Infect. Dis. 1990; 162: 1049-1054.
  27. Weibel R.E., Neff B.J., Kuter B.J. et al. Live attenuated varicella virus vaccine: efficacy trial in healthy children. New Engl. J. Med. 1984; 310: 1409-1411.
  28. Watson B., Rothstein E., Bernstein H. et al. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J. Infect. Dis. 1995; 72: 217-219.
  29. Sperber S., Smith B.V., Hayden F.G. Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine. Antiviral. Res. 1992; 17: 213-222.
  30. Watson B., Piercy S., Soppas D. et al. The effect of decreasing amounts of live virus, while antigen content remainsconstant, on immunogenicity of Oka/Merck varicella vaccine. J. Infect. Dis. 1993; 168: 1356-1360.
  31. Watson B., Boardman C., Laufer D. et al. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin. Infect. Dis. 1995; 20: 316-319.
  32. Nader S., Bergen R., Sharp M., Arvin A.M. Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J. Infect. Dis. 1995; 171: 13-17.
  33. Robert Koch Institut: Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut / Stand: Juli 2006. Epidemiol. Bull. 2006; 30: 235-254.
  34. Robert Koch Institut: Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut / Stand: Juli 2007. Epidemiol. Bull. 2007; 30: 267-286.
  35. Siedler A., Arndt U. Varicella sentinel in Germany shows success of vaccination. 26th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Graz, Austria .13-17 May 2008.
  36. Shinefield H., Black S., Digilio L. et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediat. Infect. Dis. J. 2005; 24: 665-669.
  37. Ngai A.L., Staehle B.O., Kuter B.J. et al. Safety and immunogenicity of 1 vs. 2 injections of Oka/Merck varicella vaccine in healthy children. Pediat. Infect. Dis. J. 1996; 15: 49-54.
  38. Lieberman J.M., Williams W.R., Miller J.M. et al. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediat. Infect. Dis. J. 2006; 25: 615-622.
  39. Kuter B., Matthews H., Shinefield H. et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediat. Infect. Dis. J. 2004; 23: 132-137.
  40. Reisinger K.S., Brown M.L., Xu J. et al. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. Pediatrics2006; 117: 265-272.
  41. MMR vaccination overview in European countries [http:// www.euvac.net/graphics/euvac/vaccination/mmr.html]
  42. World Health Organization: Measles vaccines. Wkly Epidemiol. Rec. 2004; 79: 130-142.
  43. Peltola H., Heinonen O.P., Valle M. et al. The elimination of indigenous measles, mumps and rubella from Finland by a 12-year, two-dose vaccination program. New Engl. J. Med. 1994; 331: 1397-1402.
  44. Vesikari T., Baer G., Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella (MMRV) vaccine in healthy children aged 5-6 years. Pediat. Infect. Dis. J. 2007; 26: 153-158.
  45. Ветряная оспа. Бюл. «Вакцинация» 2009; 1. http://www. privivka.ru/ru/expert/bulletin/archive/?id=2&tid=12
  46. Лыткина И.Н., Михеева И.В. Унификация системы управления эпидемическим процессом кори, эпидемического паротита и краснухи. Эпидемиол. и вакцинопрофилактика- 2011; 1(56): 8-14.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies